CGIX Analyst Day: Company and Portfolio Updates

Posted on: Thursday, October 9th, 2014

Cancer Genetics Inc. September 2014 Company and Portfolio Update

CEO Panna Sharma provides introductory remarks.

Dr. Gianrico Farrugia, Director of the Center for Individualized Medicine, Mayo Clinic, provides updates on OncoSpire, CGI’s joint venture with the Mayo Clinic.

Jane Houldsworth, Ph.D., VP of Research and Development discusses the CGI Hematological Portfolio.

Dr. Howard McLeod, Medical Director of the Miffitt Cancer Center discusses integrating pharmacogenomics into oncology.

Anna Marie Samulis, Field Product Manager for FHACT discusses FHACT, CGI’s proprietary test for cervical cancer screening.

Banumathy Gowrishankar, Ph.D., principal research scientist at CGI discusses the CGI Kidney Cancer Portfolio.

Filed Under:
Tags: CGIX

> Additional Articles

Additional Videos»

Cancer Genetics offers the FDA-approved DAKO PD-L1 IHC 22C3 pharmDx companion diagnostic test for KEYTRUDA®

The FDA approved PD-L1 (IHC) 22C3 pharmDx companion diagnostic test for KEYTRUDA® (pembrolizumab) is now available at CGI to assess PD-L1 expression in Non-Small Cell Lung Cancer
Cancer Genetics is a center of excellence for oncology-focused clinical trials.

Narasimha Marella, Ph.D., Corporate Development Manager speaks about how Cancer Genetics can help biopharma companies overcome oncology-focused clinical trial challenges. The current challenge that is faced by biotech and biopharmas that are involved in oncology drug development is their ability to accurately stratify and randomize patients for their clinical trials based on biomarkers. Despite the […]
Cancer Genetics offers an integrated solution for clinical trials.

Kristen Hopp, PMP, Senior Clinical Trial Project Associate speaks about Cancer Genetics integrated clinical trial services. In hematological malignancies one of the challenges is the diversity of subtypes. For these trials, genomic insights have become critically important. Our innovative research and our clinical expertise in these cancers makes CGI an ideal partner for these clinical […]
Cancer Genetics offers an integrated solution for Clinical Trials.

Nathan Campbell, Director of Clinical Services speaks about Cancer Genetics’ Biorepository capability and how having access to samples genomic data is important. As a clinical trial progresses and a more diverse patient population is recruited, variations in a drug’s efficacy and safety can start to arise. Unexpected adverse events can potentially kill a drug at […]